Biotech China Europe Manufacturing Pharmaceutical Renminbi Revenue Technology
Innovent Biologics, Inc. (Innovent) has announced its 2026 interim results and 2030 strategic vision. Dr. Michael Yu, Founder, Chairman of the Board and CEO of Innovent, highlighted the company’s evolution over the years, emphasizing the transition from a regional leader to a global premier biopharma. In the first half of 2026, Innovent experienced significant revenue and profit growth, solidifying its position in China’s biopharmaceutical industry and establishing strategic collaborations with global pharmaceutical leaders like Takeda, Eli Lilly, and Pfizer. Innovent achieved total revenue of RMB 8.6 billion in the first half of 2026, with product revenue reaching RMB 8.2 billion,…
News Timeline:
Track the development of this news story across the Internet.